Recent Updates
Recently added Catalysts
NVCR Positive Sentiment

JAMA Network Open Publishes Quality of Life and Pain Outcomes Data from Phase 3 PANOVA-3 Trial of Novocure’s Tumor Treating Fields for Pancreatic Cancer

Friday, November 13, 2026 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: Novocure announced that JAMA Network Open published results from the Phase 3 PANOVA-3 trial. The study analyzed quality of life and pain outcomes for patients with unresectable pancreatic adenocarcinoma treated with Tumor Treating Fields therapy alongside gemcitabine and nab-paclitaxel. The findings support the potential benefits of this treatment approach.

Market Sentiment Analysis

POSITIVE FACTORS

  • JAMA Network Open published positive outcomes data.
  • The study focused on quality of life and pain outcomes.
  • Results were from a Phase 3 trial.
  • TTFields therapy showed promise for pancreatic cancer.

Full Press Release Details

BAAR, Switzerland--(BUSINESS WIRE)--Novocure (Nasdaq: NVCR) announced today that JAMA Network Open published the results of the prespecified secondary analysis of data from the Phase 3 PANOVA-3 trial of Tumor Treating Fields (TTFields) therapy concomitant with gemcitabine and nab-paclitaxel in patients with unresectable, locally advanced pancreatic adenocarcinoma. The PANOVA-3 trial evaluated the use of TTFields therapy concomitantly with gemcitabine and nab-paclitaxel (GnP) as a first-line tre

Frequently Asked Questions

What is the PANOVA-3 trial?

The PANOVA-3 trial evaluated TTFields therapy with gemcitabine and nab-paclitaxel.

What were the outcomes published in JAMA?

The outcomes focused on quality of life and pain for pancreatic cancer patients.

What type of cancer was studied in the trial?

The trial studied patients with unresectable, locally advanced pancreatic adenocarcinoma.

Who conducted the PANOVA-3 trial?

The trial was conducted by Novocure.

ShareAdd on Google
Tags: NVCR Novocure TTFields therapy pancreatic cancer Phase 3 trial gemcitabine
Last updated: Nov 13, 2026

Biotech snapshot

Cash runway
$463M liquidity · $0M/mo burn
Low dilution risk
Lead asset
Immune checkpoint inhibitors or docetaxelPhase 3
Nonsmall Cell Lung Cancer →